Why did FMC cut its full-year outlook, and what are the new revenue and earnings projections?

FMC cut its full-year outlook due to more challenging market conditions, particularly weak farm economics driving cautious purchasing behavior by growers and a continued lag in crop protection market recovery. The company now expects revenue excluding India of $3.50 billion–$3.70 billion (down 7% at the midpoint versus 2025), and adjusted earnings of $1.19–$1.49 per share (down 55% at the midpoint), compared to its prior April forecast of $3.6 billion–$3.8 billion in revenue and $1.63–$1.89 per share in adjusted EPS.

What strategic financial actions did FMC take in Q2 to strengthen its balance sheet?

In Q2, FMC executed several transactions to strengthen its financial foundation and improve flexibility: concluding its strategic review; securing a $400-million minority equity investment from Tessenderlo Group; completing a $114-million sale-leaseback of its Newark, Delaware property; receiving a $200-million upfront licensing payment tied to rimisoxafen; and agreeing to sell its India commercial crop protection business to Crystal Crop Protection for $252 million, with expected closure by year-end 2026.